Samuel H Zuvekas1, Benedetto Vitiello. 1. Center for Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality, Rockville, MD, USA.
Abstract
OBJECTIVE: The authors examined the utilization of stimulant medications for the treatment of ADHD in U.S. children during the period 1996–2008 to determine trends by age, sex, race/ethnicity, family income, and geographic region. METHOD: The 1996–2008 database of the Medical Expenditure Panel Survey, a nationally representative annual survey of U.S. households, was analyzed for therapeutic stimulant use in children age 18 and younger. The data for 1987 were also recalculated for reference. RESULTS: An estimated 3.5% (95% confidence interval=3.0–4.1) of U.S. children received stimulant medication in 2008, up from 2.4% in 1996. Over the period 1996–2008, stimulant use increased consistently at an overall annual growth rate of 3.4%. Use increased in adolescents (annual growth, 6.5%), but it did not significantly change in 6- to 12-year-olds, and it decreased in preschoolers. Use remained higher in boys than in girls, and it remained consistently lower in the West than in other U.S. regions. While differences by family income have disappeared over time, use of stimulants in ADHD treatment is significantly lower in racial/ethnic minorities. CONCLUSIONS: Overall, pediatric stimulant use has been slowly but steadily increasing since 1996, primarily as a result of greater use in adolescents. Use in preschoolers remains low and has declined over time. Important variations related to racial/ethnic background and geographic region persist, thus indicating a substantial heterogeneity in the approach to the treatment of ADHD in U.S. communities.
OBJECTIVE: The authors examined the utilization of stimulant medications for the treatment of ADHD in U.S. children during the period 1996–2008 to determine trends by age, sex, race/ethnicity, family income, and geographic region. METHOD: The 1996–2008 database of the Medical Expenditure Panel Survey, a nationally representative annual survey of U.S. households, was analyzed for therapeutic stimulant use in children age 18 and younger. The data for 1987 were also recalculated for reference. RESULTS: An estimated 3.5% (95% confidence interval=3.0–4.1) of U.S. children received stimulant medication in 2008, up from 2.4% in 1996. Over the period 1996–2008, stimulant use increased consistently at an overall annual growth rate of 3.4%. Use increased in adolescents (annual growth, 6.5%), but it did not significantly change in 6- to 12-year-olds, and it decreased in preschoolers. Use remained higher in boys than in girls, and it remained consistently lower in the West than in other U.S. regions. While differences by family income have disappeared over time, use of stimulants in ADHD treatment is significantly lower in racial/ethnic minorities. CONCLUSIONS: Overall, pediatric stimulant use has been slowly but steadily increasing since 1996, primarily as a result of greater use in adolescents. Use in preschoolers remains low and has declined over time. Important variations related to racial/ethnic background and geographic region persist, thus indicating a substantial heterogeneity in the approach to the treatment of ADHD in U.S. communities.
Authors: Julie Magno Zito; Daniel J Safer; Susan DosReis; James F Gardner; Laurence Magder; Karen Soeken; Myde Boles; Frances Lynch; Mark A Riddle Journal: Arch Pediatr Adolesc Med Date: 2003-01
Authors: Laurence Greenhill; Scott Kollins; Howard Abikoff; James McCracken; Mark Riddle; James Swanson; James McGough; Sharon Wigal; Tim Wigal; Benedetto Vitiello; Anne Skrobala; Kelly Posner; Jaswinder Ghuman; Charles Cunningham; Mark Davies; Shirley Chuang; Tom Cooper Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-11 Impact factor: 8.829
Authors: Sean Esteban McCabe; Philip Veliz; Timothy E Wilens; John E Schulenberg Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-12-25 Impact factor: 8.829
Authors: Wilson M Compton; Beth Han; Carlos Blanco; Kimberly Johnson; Christopher M Jones Journal: Am J Psychiatry Date: 2018-04-16 Impact factor: 18.112
Authors: Susanna N Visser; Rebecca H Bitsko; Melissa L Danielson; Reem M Ghandour; Stephen J Blumberg; Laura A Schieve; Joseph R Holbrook; Mark L Wolraich; Steven P Cuffe Journal: J Pediatr Date: 2015-04-01 Impact factor: 4.406
Authors: Lisa L Weyandt; Danielle R Oster; Marisa E Marraccini; Bergljot Gyda Gudmundsdottir; Bailey A Munro; Emma S Rathkey; Alison McCallum Journal: Exp Clin Psychopharmacol Date: 2016-10 Impact factor: 3.157
Authors: Mark A Riddle; Kseniya Yershova; Deborah Lazzaretto; Natalya Paykina; Gayane Yenokyan; Laurence Greenhill; Howard Abikoff; Benedetto Vitiello; Tim Wigal; James T McCracken; Scott H Kollins; Desiree W Murray; Sharon Wigal; Elizabeth Kastelic; James J McGough; Susan dosReis; Audrey Bauzó-Rosario; Annamarie Stehli; Kelly Posner Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-02-08 Impact factor: 8.829